Document Detail

Comparison of kaolin and tissue factor activated thromboelastography in haemophilia.
MedLine Citation:
PMID:  20028419     Owner:  NLM     Status:  MEDLINE    
A limitation of bypassing agent therapy for haemophilia patients with inhibitors is the absence of a laboratory assay, which predicts the clinical response to treatment. Recent investigations have demonstrated the potential for thromboelastography to assess the effects of bypassing agent therapy in this patient population. While tissue factor activation has been used in several prior studies, a recent multicentre study failed to demonstrate an expected concentration-response effect of rFVIIa and called into question the tissue factor activation methods that have been employed. A comparison of kaolin to two concentrations of tissue factor as the activation method for thromboelastography was investigated in patients with haemophilia. We performed kaolin and tissue factor activated thromboelastography on blood from inhibitor and non-inhibitor patients with and without addition of rFVIIa and rFVIII. The results demonstrate that kaolin leads to a longer R, K and angle than the higher dilution of tissue factor (1:17 000) at baseline (no factor) and after addition of rFVIIa for both the inhibitor and non-inhibitor patients. Kaolin led to a longer R and K in comparison to a low dilution of tissue factor (1:42 000) following the addition of rFVIIa in the inhibitor patients. The longer R and K allows for better discrimination of the effects of rFVIIa thus making kaolin the most sensitive activation method in this setting. Thus kaolin activated thromboelastography should be considered an effective, perhaps the most effective, activator when utilizing thromboelastography to assess the effects of rFVIIa in haemophilia patients with inhibitors.
G Young; R Zhang; R Miller; D Yassin; D J Nugent
Related Documents :
15470279 - Combination of thrombophilia markers in acute myocardial infarction of the young.
1379429 - Analysis of intraarticular fibrinolytic pathways in patients with inflammatory and noni...
2506659 - Clotting activation and impairment of fibrinolysis in malignancy.
21091389 - Lumbar radiculopathy caused by foraminal stenosis in rheumatoid arthritis.
20968199 - Evolution of chronic hypertensive nephropathies treated with ace inhibitors on patients...
11554939 - Early transfusion of factor viii/von willebrand factor concentrates seems to be effecti...
21155089 - Clinicopathologic characteristics of cutaneous chronic graft-versus-host diseases: a re...
19308429 - The right-sided aortic arch in children with esophageal atresia and tracheo-esophageal ...
1208849 - Impaired ventilation in a patient with angiographically demonstrated pulmonary emboli.
Publication Detail:
Type:  Journal Article     Date:  2009-12-17
Journal Detail:
Title:  Haemophilia : the official journal of the World Federation of Hemophilia     Volume:  16     ISSN:  1365-2516     ISO Abbreviation:  Haemophilia     Publication Date:  2010 May 
Date Detail:
Created Date:  2010-06-11     Completed Date:  2010-09-16     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9442916     Medline TA:  Haemophilia     Country:  England    
Other Details:
Languages:  eng     Pagination:  518-24     Citation Subset:  IM    
Division of Hematology/Oncology, Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA 90027, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Blood Coagulation / drug effects
Drug Interactions
Factor VIII / pharmacology*
Factor VIIa / pharmacology*
Hemophilia A / blood,  drug therapy*
Kaolin / pharmacology*,  therapeutic use
Recombinant Proteins / pharmacology
Thrombelastography / methods*
Young Adult
Reg. No./Substance:
0/Recombinant Proteins; 0/recombinant FVIIa; 1332-58-7/Kaolin; 9001-27-8/Factor VIII; EC VIIa

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Synergistic action of the novel HSP90 inhibitor NVP-AUY922 with histone deacetylase inhibitors, melp...
Next Document:  Assessing the benefits of FEIBA prophylaxis in haemophilia patients with inhibitors.